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222) before, and 153 cells/microliter (IQR, 49—187; p = 0.3)
after DAART. Among those who no longer met the treat-
ment failure criteria after DAART, the median CD4 counts
were 150 cells/microliter (IQR, 113-233) before, and 244
cells/microliter (IQR, 132—287; p = 0.02) after DAART. At
the time of this analysis, the women who responded to
DAART have remained on ﬁrst-line therapy without addi-
tional episodes of treatment failure for amedian of 170 (IQR,
57—450) days.
Conclusions: One month of DAART with adherence coun-
seling could provide a simple, low-cost method of optimizing
the durability of response to ﬁrst-line ART and distinguishing
faltering adherence from treatment failure.
doi:10.1016/j.ijid.2008.05.500
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Background: The 1994 International Conference on Pop-
ulation and Development in Cairo, Egypt drew attention to
comprehensive reproductive health for women. The central
role of reproduction in the lives of women in many parts
of the world is now recognized. We assessed the frequency
of reproductive-organ disease in a cohort of HIV-positive
women with a view to determine the effect of HAART on
their frequency of occurrence.
Methods: 369 HIV-positive women aged between 15
to 64 years were recruited. Demographic data, history
of reproductive organ disease and use of HAART were
obtained. Pelvic examination was carried and Pap smears
were obtained for cytology.
Results: The mean age for those on HAART was 34.8± 7.3
and 33.4± 7.3 years for the HAART naive group (p = 0.08).
Mean duration of HAART use was 14.7± 11.5 months. Fre-
quency of reproductive-organ symptoms and examination
ﬁndings between the two groups (no HAART vs HAART)
are as follows; amenorrhea −80.7% vs 22.0% (p 0.001),
vaginal discharge −83.3% vs 16.7 (p 0.01), vaginal itching
−84.0% vs 16.0% (p < 0.001), irregular menses −81.7% vs
18.3% (p < 0.001), post-coital bleeding -86.7% vs 13.3% (p
0.06), history of previous STI −66.5% vs 33.5% (p 0.34), lower
abdominal pain −77.6% vs 22.4% (p 0.12), genital warts
−73.3% vs 26.7% (p 0.51), genital ulcers −68.5% vs 31.5% (p
0.91), cervical motion tenderness −87.0% vs 13.0% (p 0.05),
contact bleeding −76.2% vs 23.8% (p 0.05), abnormal cytol-
ogy −69.4% vs 30.6% (p 0.83), other abnormal lesions −73.2%
vs 26.8% (p 0.19).
Conclusion: This study revealed a higher frequency of
reproductive-organ disease in HIV-positive women who are
HAART na¨ıve compared with those on HAART. Treating HIV-
infection therefore has additional sex-speciﬁc beneﬁts for
women in terms of reproductive health morbidity, and
widespread access to treatment with integration of repro-
ductive health services should be advocated.
doi:10.1016/j.ijid.2008.05.501
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Objectives: A proportion of HIV patients beginning
antiretroviral therapy (ART) develop immune restoration
disease (IRD). Longitudinal changes in plasma antibody titer
were investigated in relation to IRD in a cohort of HIV
patients beginning therapy with a range of opportunistic
infections.
Design: Plasma were collected from 20 male (16 Chinese
and 4 Malay) HIV patients beginning ART with <100 CD4 T-
cells/l at the University of Malaya Medical Centre, Kuala
Lumpur, on 5 occasions over the ﬁrst year of therapy. 10
patients experienced IRD [3 with suspected cytomegalovirus
(CMV) disease, 2 with cryptococcal disease, 4 with tubercu-
losis (TB) and 1 with varicella zoster virus (VZV)].
Methods: Plasma antibodies (IgG) reactive with CMV,
Cryptococcal, PPD and VZV antigens were assessed using
standard ELISA method.
Results: All patients showed high level of anti-CMV anti-
body during 12 months on ART, regardless of IRD. Antibody
reactive to cryptococcal antigen peaked only at the time of
cryptococcal IRD. Anti-PPD titers were elevated at the start
of ART in two TB IRD patients and remained high or increased
further at the time of their IRD. However, the other two
TB IRD patients retained intermediate titers throughout ﬁrst
year of ART. Anti-VZV titers were detectable in the VZV IRD
patient at the start of ART, with a marginal increment during
IRD.
Conclusions: Despite their immunodeﬁciency, HIV-
infected patients display restored antigen-speciﬁc IgG
antibody responses during 12 months of ART. The high titer
of anti-CMV IgG in most patients regardless of IRD may
reﬂect the reactivation of CMV by chronic immune activa-
tion. Generally, antibody titers were extremely variable
among cohort participants but relatively stable over time,
suggesting inherent differences in immune capacity.
doi:10.1016/j.ijid.2008.05.502
